about
Arachidonic Acid and Cerebral Ischemia Risk: A Systematic Review of Observational StudiesOxpholipin 11D: an anti-inflammatory peptide that binds cholesterol and oxidized phospholipidsThe leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.Lp-PLA2 Inhibition-The Atherosclerosis Panacea?Expression of dual nucleotides/cysteinyl-leukotrienes receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction.Study of arachidonoyl specificity in two enzymes of the PI cycle.EETs Attenuate Ox-LDL-Induced LTB4 Production and Activity by Inhibiting p38 MAPK Phosphorylation and 5-LO/BLT1 Receptor Expression in Rat Pulmonary Arterial Endothelial Cells.Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea.Adipose tissue arachidonic acid content is associated with the expression of 5-lipoxygenase in atherosclerotic plaques.Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.An eicosanoid-centric view of atherothrombotic risk factorsSafety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patientsChronic exposure to emissions from photocopiers in copy shops causes oxidative stress and systematic inflammation among photocopier operators in India.Redox signaling in cardiovascular health and disease.Anti-inflammatory therapeutics for the treatment of atherosclerosis.Leukotrienes in atherosclerosis: new target insights and future therapy perspectives.5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Regulation of atherosclerotic plaque inflammation.The effect of ghee (clarified butter) on serum lipid levels and microsomal lipid peroxidation.Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies.Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.Bioactive lipids in aortic valve stenosis-a possible link to atherosclerosis?Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases.Allergies are associated with arterial changes in young children.Association of ALOX5, LTA4H and LTC4S gene polymorphisms with ischemic stroke risk in a cohort of Chinese in east China.Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).Omega-3 fatty acids in atherosclerosis and coronary artery disease.Interaction between ALOX15 polymorphisms and coronary artery disease in North Indian population.Dietary modulation of oxylipins in cardiovascular disease and aging.Leukotriene inflammatory mediators meet their match.
P2860
Q26801643-2DA013AE-49F1-43FD-AD1A-0F7AAA3099CBQ28752575-736A6C8C-87FA-4FF3-8D5B-590DC371531EQ30234961-4023328D-C968-42F0-A88A-CC270E2336D9Q33664272-CEE15947-ECAD-475B-BDF4-D310248F319AQ34336849-7003A985-1E07-493A-8353-33A152F474D5Q34984660-9A997219-405B-4918-8045-5E247AB9B00AQ35649907-5AC386D2-411E-4EA9-8B28-204B2EF48C05Q36145246-19E87526-6F57-4BF7-9DFF-E40B6E509711Q36578662-AC8AE151-F02B-4B93-AA1D-46EB406D31B1Q36620215-A111F9AD-90A3-4A8C-BAD9-DB07077E2C42Q36952174-63FD0ED5-DCCD-4046-B076-FB7B65A15B5AQ37225387-640D4E14-FDF4-482C-B88F-50D444A23F97Q37361910-FF282103-FF86-4B9E-B694-F6C88D5E91D8Q37446110-7A6B5146-431E-4A68-AD3E-12665CFD1AD3Q37626768-E38ABF9F-082E-40A0-AD2B-26C7589BC79EQ37691248-5726ABAB-C624-4952-A2E0-45580DD2EED6Q37986694-226CFCB2-A325-494C-ACD9-13930C4B6D64Q37995534-0A915CE1-27E7-4958-AD8C-5DE316570AEEQ38396097-DAF527CB-DB41-43CE-B9CC-67FB25C56102Q39084624-91460E23-B1ED-4122-BB53-C386FD2B2339Q39649096-4F68B875-EC6A-41BD-A8B4-AE4E2093AF37Q39710240-E259B0FC-2E49-4B8B-A63B-6AC525985121Q40062794-DACA52BE-6BA0-4DED-BF5B-2D0377417989Q41432422-2B5B770B-2AAA-495F-A9B9-3BBE7FF00492Q41706957-2C5D587A-D022-484E-9E74-88AAE2656DE1Q42785053-602AF27D-BFCA-40C9-9596-227A9831D282Q43150802-7E16A5AC-60B4-4719-8849-2291B7FC662CQ46222465-F997EF02-EA37-4B66-A6EB-66905A55EA61Q47722921-A19B66F5-12F7-4C6A-A65D-E86C968865D8Q48157381-0567ABB2-7203-4598-9F1F-1C018A137F27Q48706704-3A5F6E0A-E380-4A07-B97A-4220A887AD0E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Leukotriene signaling in atherosclerosis and ischemia
@en
Leukotriene signaling in atherosclerosis and ischemia.
@nl
type
label
Leukotriene signaling in atherosclerosis and ischemia
@en
Leukotriene signaling in atherosclerosis and ischemia.
@nl
prefLabel
Leukotriene signaling in atherosclerosis and ischemia
@en
Leukotriene signaling in atherosclerosis and ischemia.
@nl
P2860
P1476
Leukotriene signaling in atherosclerosis and ischemia
@en
P2860
P356
10.1007/S10557-008-6140-9
P50
P577
2008-10-24T00:00:00Z